Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E33.45 EPS (ttm)0.51 Insider Own1.60% Shs Outstand315.38M Perf Week-2.46%
Market Cap5.24B Forward P/E22.93 EPS next Y0.74 Insider Trans-7.49% Shs Float309.61M Perf Month-19.91%
Income164.30M PEG0.73 EPS next Q0.16 Inst Own85.40% Short Float3.62% Perf Quarter-12.20%
Sales1.25B P/S4.18 EPS this Y-65.50% Inst Trans-0.91% Short Ratio6.22 Perf Half Y-24.35%
Book/sh6.70 P/B2.55 EPS next Y48.50% ROA7.20% Target Price29.77 Perf Year-8.92%
Cash/sh4.57 P/C3.73 EPS next 5Y46.00% ROE8.30% 52W Range16.19 - 25.77 Perf YTD-15.00%
Dividend- P/FCF19.04 EPS past 5Y19.70% ROI4.80% 52W High-33.26% Beta0.81
Dividend %- Quick Ratio6.10 Sales past 5Y92.70% Gross Margin96.10% 52W Low6.24% ATR0.58
Employees773 Current Ratio6.20 Sales Q/Q42.10% Oper. Margin15.50% RSI (14)32.56 Volatility3.12% 3.26%
OptionableYes Debt/Eq0.00 EPS Q/Q214.50% Profit Margin13.10% Rel Volume0.88 Prev Close17.06
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout0.00% Avg Volume1.80M Price17.20
Recom2.00 SMA20-7.69% SMA50-14.59% SMA200-18.09% Volume683,800 Change0.82%
Nov-19-21Initiated Piper Sandler Overweight $34
Nov-03-21Resumed Jefferies Buy $28
Oct-07-21Initiated Jefferies Buy $28
Aug-06-21Reiterated H.C. Wainwright Buy $35 → $64
Jun-15-21Initiated H.C. Wainwright Buy $47
May-18-21Resumed Goldman Sell $23
Mar-31-21Initiated Credit Suisse Outperform $30
Mar-12-21Initiated Wolfe Research Outperform $35
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Nov-20-21 06:00AM  
Nov-18-21 10:27AM  
Nov-12-21 05:51AM  
Nov-09-21 08:00AM  
Nov-04-21 11:21AM  
09:25AM  
06:05AM  
Nov-03-21 04:05PM  
12:45PM  
11:40AM  
08:56AM  
Nov-02-21 11:01PM  
06:25PM  
04:05PM  
Nov-01-21 10:54AM  
Oct-30-21 06:00AM  
Oct-29-21 08:50AM  
Oct-28-21 10:00AM  
Oct-26-21 03:02PM  
10:43AM  
10:39AM  
Oct-19-21 04:05PM  
10:00AM  
Oct-18-21 12:21PM  
Oct-14-21 10:02AM  
08:00AM  
08:00AM  
Oct-13-21 05:51AM  
Sep-28-21 05:51AM  
Sep-22-21 08:36AM  
Sep-20-21 11:57AM  
11:30AM  
09:51AM  
Sep-18-21 07:30AM  
Sep-17-21 04:23PM  
Sep-16-21 07:49AM  
02:30AM  
Sep-11-21 11:45AM  
Sep-06-21 01:00PM  
Sep-02-21 06:19AM  
Sep-01-21 04:05PM  
Aug-26-21 07:51AM  
05:51AM  
Aug-25-21 04:05PM  
Aug-20-21 09:11AM  
Aug-18-21 11:47AM  
Aug-17-21 08:37AM  
Aug-16-21 03:47PM  
08:05AM  
Aug-06-21 11:29AM  
09:13AM  
12:01AM  
Aug-05-21 07:15PM  
04:05PM  
08:00AM  
Aug-02-21 05:51AM  
Jul-29-21 03:05PM  
Jul-26-21 05:51AM  
Jul-22-21 04:05PM  
08:06AM  
Jul-19-21 02:45AM  
Jul-16-21 05:51AM  
Jul-13-21 10:10AM  
Jul-09-21 07:41AM  
06:55AM  
Jul-08-21 04:05PM  
Jul-02-21 05:51AM  
Jun-30-21 04:04PM  
Jun-29-21 07:03PM  
Jun-28-21 04:15PM  
12:04PM  
01:00AM  
Jun-18-21 08:00AM  
05:51AM  
Jun-15-21 11:39AM  
Jun-14-21 08:00AM  
Jun-07-21 08:00AM  
Jun-06-21 10:06AM  
Jun-04-21 09:00AM  
09:00AM  
09:00AM  
May-30-21 06:00AM  
May-26-21 04:15PM  
06:06AM  
May-25-21 10:51AM  
07:48AM  
May-24-21 04:05PM  
May-22-21 06:30AM  
May-21-21 06:31AM  
May-20-21 01:35AM  
May-09-21 02:06PM  
May-07-21 01:04PM  
11:30AM  
05:51AM  
May-06-21 07:05PM  
04:05PM  
03:15PM  
May-04-21 08:00AM  
Apr-27-21 04:05PM  
Apr-26-21 09:29AM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haley Patrick J.EVP, CommercialNov 24Sale17.2517,236297,321237,802Nov 26 07:39 PM
FELDBAUM CARL BDirectorNov 19Option Exercise3.1320,00062,60028,521Nov 23 08:11 PM
FELDBAUM CARL BDirectorNov 19Sale17.6220,000352,4008,521Nov 23 08:11 PM
Lamb PeterEVP, Scientific Strategy & CSONov 15Option Exercise6.2147,500294,975458,740Nov 17 08:02 PM
Lamb PeterEVP, Scientific Strategy & CSONov 15Sale18.0947,500859,275411,240Nov 17 08:02 PM
Hessekiel JeffreyEVP and General CounselNov 01Sale22.035,117112,728632,825Nov 03 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOOct 15Option Exercise6.2147,500294,975458,740Oct 15 08:15 PM
Lamb PeterEVP, Scientific Strategy & CSOOct 15Sale21.9247,5001,041,200411,240Oct 15 08:15 PM
Hessekiel JeffreyEVP and General CounselOct 15Sale22.0212,883283,684637,942Oct 15 08:14 PM
Senner Christopher J.EVP and CFOSep 21Option Exercise3.6690,000329,400446,591Sep 23 08:16 PM
Haley Patrick J.EVP, CommercialSep 16Option Exercise1.7025,00042,500305,994Sep 17 07:58 PM
Haley Patrick J.EVP, CommercialSep 16Sale20.3625,000509,000280,994Sep 17 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSOSep 15Option Exercise6.2147,500294,975436,967Sep 17 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOSep 15Sale20.4647,500971,850389,467Sep 17 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOAug 16Option Exercise1.9055,000104,500444,467Aug 18 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOAug 16Sale18.4455,0001,014,200389,467Aug 18 07:56 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJul 26Option Exercise4.2040,000168,000689,078Jul 28 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJul 21Option Exercise4.2035,000147,000649,078Jul 23 07:47 PM
Lamb PeterEVP, Scientific Strategy & CSOJul 15Option Exercise1.9060,000114,000449,467Jul 16 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSOJul 15Sale17.4760,0001,048,200389,467Jul 16 07:58 PM
COHEN CHARLESDirectorJul 06Option Exercise4.7180,000377,200261,375Jul 08 07:45 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Option Exercise1.9060,000114,000449,467Jun 22 08:03 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Sale22.1860,0001,330,800389,467Jun 22 08:03 PM
Haley Patrick J.EVP, CommercialMay 18Sale24.7314,593360,885280,994May 18 08:13 PM
MARCHESI VINCENT TDirectorMay 14Option Exercise6.3040,000252,000106,115May 17 08:13 PM
MARCHESI VINCENT TDirectorMay 14Sale25.0440,0001,001,60066,115May 17 08:13 PM
POSTE GEORGEDirectorMay 14Sale24.9740,8021,018,826157,190May 17 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMay 13Option Exercise1.90100,000190,000714,078May 14 08:35 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMay 13Sale25.38100,0002,538,000614,078May 14 08:35 PM
MORRISSEY MICHAELPresident and CEOMay 12Option Exercise4.2050,000210,000541,813May 14 08:51 PM
PAPADOPOULOS STELIOSDirectorMay 11Option Exercise4.27120,000512,4001,293,600May 13 08:32 PM
PAPADOPOULOS STELIOSDirectorMay 11Sale24.9820,770518,7941,218,675May 13 08:32 PM
Freire Maria CDirectorMay 11Sale25.018,275206,95831,827May 17 08:15 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 26Option Exercise1.7050,00085,000663,482Apr 28 08:10 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 26Sale25.0050,0001,250,000613,482Apr 28 08:10 PM
Haley Patrick J.EVP, CommercialApr 26Sale25.037,665191,855297,392Apr 28 08:08 PM
Hessekiel JeffreyEVP and General CounselApr 26Sale25.0318,000450,540628,248Apr 28 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 01Option Exercise1.7050,00085,000663,482Apr 02 07:41 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 01Option Exercise1.7060,000102,000449,467Apr 02 07:51 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 01Sale22.9660,0001,377,600389,467Apr 02 07:51 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 01Sale23.0050,0001,150,000613,482Apr 02 07:41 PM
WYSZOMIERSKI JACK LDirectorMar 29Option Exercise3.3840,000135,200237,809Mar 31 09:02 PM
WYSZOMIERSKI JACK LDirectorMar 29Sale22.646,220140,821231,589Mar 31 09:02 PM
Garber Alan MDirectorMar 15Option Exercise3.3840,000135,20052,718Mar 17 08:11 PM
Garber Alan MDirectorMar 15Sale23.6040,000944,00012,718Mar 17 08:11 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise1.7065,000110,500405,072Mar 03 07:49 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1165,0001,437,150340,072Mar 03 07:49 PM
COHEN CHARLESDirectorFeb 24Option Exercise3.3840,000135,200221,375Feb 26 08:10 PM
COHEN CHARLESDirectorFeb 24Sale22.6940,000907,600181,375Feb 26 08:10 PM
WILLSEY LANCEDirectorFeb 23Option Exercise3.3840,000135,200464,415Feb 24 08:11 PM
WILLSEY LANCEDirectorFeb 23Sale21.9340,000877,136424,415Feb 24 08:11 PM
POSTE GEORGEDirectorFeb 22Option Exercise3.3840,000135,200197,992Feb 24 08:18 PM
MARCHESI VINCENT TDirectorFeb 22Sale22.2924,097537,12266,115Feb 24 08:15 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 18Option Exercise1.7050,00085,000590,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 18Sale22.3550,0001,117,500540,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 17Option Exercise1.7050,00085,000590,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 17Sale22.5050,0001,125,000540,597Feb 19 07:57 PM
FELDBAUM CARL BDirectorFeb 16Option Exercise3.3820,00067,60028,521Feb 17 08:03 PM
FELDBAUM CARL BDirectorFeb 16Sale21.9620,000439,2008,521Feb 17 08:03 PM
WILLSEY LANCEDirectorFeb 16Sale21.9050,0001,095,000424,415Feb 24 08:11 PM
Haley Patrick J.EVP, CommercialFeb 12Sale21.5745,000970,650246,887Feb 17 08:15 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise1.7065,000110,500348,124Feb 03 07:57 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale22.0865,0001,435,200283,124Feb 03 07:57 PM
Senner Christopher J.EVP and CFOJan 12Option Exercise3.6630,000109,800275,596Jan 14 08:22 PM
Senner Christopher J.EVP and CFOJan 12Sale25.0030,000750,000245,596Jan 14 08:22 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Option Exercise1.7065,000110,500348,124Jan 06 08:40 PM
Hessekiel JeffreyEVP and General CounselJan 04Option Exercise5.1250,000256,100541,754Jan 06 08:22 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Sale20.3265,0001,320,800283,124Jan 06 08:40 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Option Exercise1.7065,000110,500348,124Dec 22 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Sale20.0165,0001,300,650283,124Dec 22 07:58 PM
WILLSEY LANCEDirectorDec 04Option Exercise5.82106,142617,746474,415Dec 04 07:56 PM